IP Library Granted Patent US 9,528,126
Granted Patent B2
US 9,528,126 · App. 13/368,167 · Granted Dec 27, 2016

Methods for producing preparations of recombinant AAV virions substantially free of empty capsids

Inventors: Guang Qu (Alameda, CA); John Fraser Wright (Mill Valley, CA)
Assignee: Genzyme Corporation
C12N15/86C12N7/00C12N2750/14143C12N2750/14151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,528,126
App. No.
13/368,167
Granted
Dec 27, 2016
Kind
B2
Abstract

Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.

Claims (35)

1. A method for purifying AAV vector particles from an AAV preparation comprising AAV vector particles and AAV empty capsids, to provide an AAV product substantially free of AAV empty capsids, said method comprising:

(a) applying an AAV preparation comprising AAV vector particles and AAV empty capsids to a cation exchange chromatography column under conditions whereby said AAV vector particles and said AAV empty capsids bind the column;

(b) adding a salt buffer to the column from (a) under conditions whereby AAV vector particles are eluted and AAV empty capsids remain bound to the column;

(c) collecting eluted fractions from (b) that comprise AAV vector particles;

(d) applying the fractions from step (c) to an anion exchange chromatography column under conditions whereby said AAV vector particles and AAV empty capsids, if present, bind the column;

(e) adding a salt buffer to the column from (d) under conditions whereby AAV empty capsids are eluted and AAV vector particles remain bound to the column;

(f) adding a buffer with a greater salt concentration relative to the buffer added in (e) to the column from (e) under conditions whereby AAV vector particles are eluted;

(g) collecting eluted fractions from (f) and selecting fractions that consist essentially of AAV vector particles to provide an AAV product substantially free of AAV empty capsids, wherein AAV vector particles are present in said AAV product in an amount of at least 75%.

2. The method of claim 1 , wherein said cation exchange column comprises a carboxymethylated or sulfonated matrix.

3. The method of claim 2 , wherein said matrix comprises the functional ligand R—SO 3 —.

4. The method of claim 1 , wherein AAV vector particles are present in said AAV product in an amount of at least 85%.

5. The method of claim 1 , wherein AAV vector particles are present in said AAV product in an amount of at least 90%.

6. The method of claim 1 , wherein said AAV vector particles are derived from AAV-2.

7. The method of claim 1 , wherein said AAV vector particles are derived from AAV-5.

8. The method of claim 1 , further comprising:

(h) applying the AAV preparation from (g) to a second anion exchange chromatography column under conditions whereby said AAV vector particles and said AAV empty capsids, if present, bind the column;

(i) adding a salt buffer to the column from (h) under conditions whereby AAV empty capsids are eluted and AAV vector particles remain bound to the column;

(j) adding a salt buffer with a greater salt concentration relative to the buffer added in (i) to the column from (i) under conditions whereby AAV vector particles are eluted;

(k) collecting eluted fractions from (j) that comprise AAV vector particles to provide an AAV product substantially free of AAV empty capsids.

9. The method of claim 8 , further comprising:

(l) applying the AAV preparation from (k) to a second cation exchange chromatography column under conditions whereby said AAV vector particles and said AAV empty capsids bind the column;

(m) adding a salt buffer to the column from (l) under conditions whereby AAV vector particles are eluted and AAV empty capsids remain bound to the column; and

(o) collecting eluted fractions from (m) that comprise AAV vector particles to provide an AAV product substantially free of AAV empty capsids.

10. A method for purifying AAV vector particles from an AAV preparation comprising AAV vector particles and AAV empty capsids, to provide an AAV product substantially free of AAV empty capsids, said method comprising:

(a) applying an AAV preparation comprising AAV vector particles and AAV empty capsids to a cation exchange chromatography column under conditions whereby said AAV vector particles and said AAV empty capsids bind the column;

(b) adding a salt buffer to the column from (a) under conditions whereby AAV vector particles are eluted and AAV empty capsids remain bound to the column;

(c) collecting eluted fractions from (b) that comprise AAV vector particles;

(d) applying the AAV preparation from (c) to a second cation exchange chromatography column under conditions whereby said AAV vector particles and said AAV empty capsids bind the column;

(e) adding a salt buffer to the column from (d) under conditions whereby AAV vector particles are eluted and AAV empty capsids remain bound to the column; and

(f) collecting eluted fractions from (e) that comprise AAV vector particles to provide an AAV product substantially free of AAV empty capsids.

11. The method of claim 10 , further comprising:

(g) applying the fractions from step (f) to an anion exchange chromatography column under conditions whereby said AAV vector particles and AAV empty capsids, if present, bind the column;

(h) adding a salt buffer to the column from (g) under conditions whereby AAV empty capsids are eluted and AAV vector particles remain bound to the column;

(i) adding a salt buffer with a greater salt concentration relative to the buffer added in (h) to the column from (h) under conditions whereby AAV vector particles are eluted; and

(j) collecting eluted fractions from (i) that comprise AAV vector particles to provide an AAV product substantially free of AAV empty capsids.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2020
From: QU, GUANG; WRIGHT, JOHN FRASER
To: AVIGEN, INC.
Reel/Frame 053221/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2020
From: AVIGEN, INC.
To: GENZYME CORPORATION
Reel/Frame 053221/0560 →
Continuity (5)
Continuation 11809655 · Jun 1, 2007
Division 10851688 · May 21, 2004
Provisional Application 60472384 · May 21, 2003
Provisional Application 60549756 · Mar 2, 2004
Related Publication 20120135515A1 · May 31, 2012